Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). ASH 2016.
Results From Ongoing Phase 2 Trial of SL-401 as Consolidation Therapy in Patients With Acute Myeloid Leukemia (AML) in Remission With High Relapse Risk Including Minimal Residual Disease (MRD)
January 8, 2016